Nasus Pharma Ltd (NSRX) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access NSRX Annual Income Statement →
Reviewing income statement figures over time helps illustrate how Nasus Pharma Ltd generates earnings and manages operating expenses.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing2.67
Research and Development Expense2.24
Total operating costs including COS4.90
Operating income / -loss-4.90
Net Interest (-)Expense / Income0.00
Other loss / -income0.90
Total costs & expenses5.81
Income & Taxes
Income / -loss before income taxes-5.81
Income after income taxes-5.81
Income / -loss from continuing operations-5.81
Discontinued operations-0.05
Net income / -loss-5.86
Income / -loss to shareholder-5.86
EBIT-5.81
EBITD-5.81
EBITDA-5.81
Earnings Per Share
Basic EPS (excl. extra items)-0.72
Extraordinary items0.00
Basic Net EPS-0.72
Basic shares outstanding (Mill. of Units)8.01
Diluted Net EPS-0.72
Diluted average shares (Mill. of Units)8.01
4 historic quarters locked

Sign in to unlock the full Nasus Pharma Ltd income statement history.

About NSRX Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI